4-factor prothrombin complex concentrate regulatory update

FDA accepted for review a BLA from CSL for 4-factor prothrombin complex concentrate (PCC) to reverse vitamin K antagonist therapy, including warfarin, in patients with acute major bleeding. The PDUFA ...